Lexicon Pharma (LXRX) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.15 +6.97%
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -86.1%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $160 thousand versus the consensus estimate of $2.06 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
- Accenture downgraded by TD Cowen on AI concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
